Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Papilocare®: Effects on Regression of Histologically Confirmed Cervical Intraepithelial Lesions 1 and Tolerance (PAPILOCARE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04624568
Recruitment Status : Recruiting
First Posted : November 12, 2020
Last Update Posted : November 11, 2021
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Régional d'Orléans

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
clinical trial comparing the regression rate after 12 months of histologically confirmed cervical intraepithelial lesions 1 in 2 parallel groups. One group using the vaginal gel Papilocare® for 6 months and one group without any treatment.

Condition or disease Intervention/treatment Phase
Squamous Intraepithelial Lesions of the Cervix Human Papilloma Virus Infection Cervix Lesion Device: PAPILOCARE Not Applicable

Detailed Description:

Cervical cancer affects 3000 women and causes 1100 deaths every year in France. This type of cancer usually takes about 10 to 15 years to develop and has distinct precursor stages. Persistent infection by Human Papillomavirus is necessary for the development of these lesions.

Currently, when a colposcopy biopsy reveals low grade lesion, it is recommanded to make a new cervical cytology or HPV testing, 12 months later. No treatment is recommended over this period. However 11% of these lesions evolve from low to high grade.

Papilocare® is a vaginal gel that would improve the re-epithelialization of the uterine cervix. Creating a protective film on the cervix, it could induce a favorable environment for regression of the cervical intraepithelial lesions 1 and for clearance of Human Papillomavirus.

The goal of our study is to include 150 women with a histologically confirmed cervical intraepithelial lesions 1. Half of them will be using the vaginal gel Papilocare® for 6 month while the other half will not receive any treatment (as suggested by current recommendations). Each patient will have a cervical cytology and a HPV testing after 6 months and after 12 months. Therefore we will be able to compare the percentage of normalization of cervical cytology and HPV clearance for each group after 6 months and after 12 months.

Patients will visit the Orleans hospital once for the inclusion and twice for follow-ups after 6 months and 12 months.

If the use of Papilocare® really induces a significant regression of low grade lesions, this vaginal gel could be offered as soon as these lesions are histologically identified in order to stop its progress to high grade.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

clinical trial with 2 parallel groups :

  1. Treatment arm : Use of the vaginal gel for the first 6 months, then absence of treatment for the next 6 months until follow-up.

    • First month : 1 cannula of Papilocare® per day except the last 7 days of the month.
    • The next five months : alternate days except the last 7 days of the month.
  2. Control arm - Absence of treatment for 12 months.

Inclusion of 150 patients, balanced randomization meaning 75 patients in each arm.

Follow-up after 6 months : a cervical cytology and a HPV testing for each patient + listing how many patients suffer from vaginal discomfort for 6 months.

Follow-up after 12 months : a cervical cytology and a HPV testing for each patient.
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Papilocare®: Effects on Regression of Histologically Confirmed Cervical Intraepithelial Lesions 1 and Tolerance.
Actual Study Start Date : November 17, 2020
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : May 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Papilocare group

Papilocare® for 6 months according to the following schedule:

1 self-applying single dose per day for 21 days over 28 during the first month, then 1 day over 2 during the following 5 months, with a 7-day break during the menstrual period. (This break must be respected even in menopausal women or women undergoing artificial amenorrhea (amenorrhea induced by certain contraceptives: implant, hormonal IUD, micro-progestogen).

 Device: PAPILOCARE

Papilocare® is a self-administered vaginal gel. Its single-dose cannula contains hyaluronic acid and pre-biotics (Coriolus Versicolor) that would improve the re-epithelialization of the uterin cervix. By creating a protective film on the cervix, this gel could induce a favorable environment for regression of the cervical intraepithelial lesions 1 and for clearance of Human Papillomavirus.

The specific approach related to our study would be to apply Papilocare® vaginal gel for 6 months for the treated group.

Smear and HPV test will be perform by all patients at 6 and 12 months.
No Intervention: Control group
No treatment for 12 months. Smear and HPV test will be perform by all patients at 6 and 12 months


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Cervical cytology normalization after 12 months. [ Time Frame: Month 12 ]

    Compare the normalization rate of the cervical cytology in each arm after 12 months.

    The difference will be considered statistically significant if the treatment group has a normalization rate of 25% or higher.

    An "unsatisfactory" smear in its realization will have to be repeated within 45 days.



Secondary Outcome Measures :
  1. Cervical cytology normalization after 6 months. [ Time Frame: Month 6 ]
    Compare the normalization rate of the cervical cytology in each arm after 6 months.

  2. HPV clearance after 6 months [ Time Frame: Month 6 ]

    2) Compare in each arm the rate of transition from a positive HPV testing at inclusion to a negative HPV testing after 6 months.

    The difference will be considered statistically significant if the treatment group has a clearance rate of 25% or higher.


  3. HPV clearance after 12 months [ Time Frame: Month 12 ]

    2) Compare in each arm the rate of transition from a positive HPV testing at inclusion to a negative HPV testing after 12 months.

    The difference will be considered statistically significant if the treatment group has a clearance rate of 25% or higher.


  4. Evaluation of tolerance of Papilocare vaginal gel [ Time Frame: Month 6 ]
    Compare in each group the number of episodes of vaginal discomfort over the first 6 months.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women aged 25 years old or older.
  • With histologically-confirmed cervical intraepithelial lesion 1 only, proven by colposcopy biopsy, done in the most suspiscious area.
  • With complete colposcopy, performed less than 3 months prior the inclusion
  • With confirmed ASC-US or LSIL cervical-cytology, performed less than 6 months prior the colposcopy.

Exclusion Criteria:

  • Women under guardianship or curatorship
  • Women under the protection of justice
  • Women not affiliated with a social security system
  • Pregnant woman (as vaginal gel has not been evaluated in pregnant women) Urinary dosing of BHCG will be performed on the day of inclusion for all women under 55 years of age and effective contraception is recommended during the study for all non-menopausal women.
  • Immunodepressed women (HIV, immunosuppressive treatments ...)
  • Woman using vaginal contraceptives (ring, spermicides, cervical cap; because of risk of interaction) NB: Papilocare is compatible with the use of condoms and intrauterine devices.
  • Known allergy to one of the components
  • Patients with low-grade histology with HSIL - ASC-H - AGC smear will not be included. The cyto-colposcopic discordance suggests a high-grade lesion that would not have been biopsied at colposcopy.
  • Patients undergoing laser or conization treatment according to the recommendations of INCa 2016 will not be included; namely: persistence of CIN 1 for more than 24 months on at least 2 different colposcopies; high-grade squamous intraepithelial histological lesions; adenocarcinoma in situ.
  • Participation in another interventional study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04624568


Contacts
Layout table for location contacts
Contact: Aurélie DESPUJOLS +33238744071 aurelie.despujols@chr-orleans.fr
Contact: Elodie POUGOUE TOUKO +33238744086 elodie.pougoue-touko@chr-orleans.fr

Locations
Layout table for location information
France
Centre Hospitalier Régional d'Orléans, France Recruiting
Orléans, France, 45000
Contact: Helene GBAGUIDI, MD       helene.gbaguidi@chr-orleans.fr   
Contact: Sarah DENAIS       sarah.denais@gmail.com   
Principal Investigator: Helene GBAGUIDI, Dr         
Sponsors and Collaborators
Centre Hospitalier Régional d'Orléans
Investigators
Layout table for investigator information
Principal Investigator: Helene GBAGUIDI, Dr CHR ORLEANS
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Other Publications:

Layout table for additonal information
Responsible Party: Centre Hospitalier Régional d'Orléans
ClinicalTrials.gov Identifier: NCT04624568    
Other Study ID Numbers: CHRO-2020-13
First Posted: November 12, 2020    Key Record Dates
Last Update Posted: November 11, 2021
Last Verified: November 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Centre Hospitalier Régional d'Orléans:
Cervical lesion
Cervical intraepithelial lesions 1
CIN1
Low grade lesion
Colposcopy
Cervical cytology
 Human Papillomavirus
HPV infection
HPV testing
Vaginal gel
Papilocare®
Additional relevant MeSH terms:
Layout table for MeSH terms
Papillomavirus Infections
Papilloma
Squamous Intraepithelial Lesions of the Cervix
Infections
Virus Diseases
Neoplasms, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
 Neoplasms
Uterine Cervical Dysplasia
Precancerous Conditions
Uterine Cervical Diseases
Uterine Diseases
DNA Virus Infections
Tumor Virus Infections